0QW0.LSE Argen-X

Healthcare Commercial Services & Supplies London Exchange
412.13 EUR
Close of Nov 3, 2026
569.00 924.70
Market cap
EUR 13.4B
P/E
-
P/B
-
ROE
39.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is 0QW0.LSE undervalued?

Graham number

The Graham number of Argen-X cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Argen-X fundamental analysis

No fundamental analysis for Argen-X yet.

Argen-X stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Argen-X

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis …

Full company profile